Pathobiology of pulmonary hypertension in infants and children

Progress in Pediatric Cardiology

Volumn 12, Issue 3, 2001, Pages 249-269

  Haworth, Sheila G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adaptation to extra uterine life; Nitric oxide; Pulmonary arteries; Pulmonary hypertension; Remodelling

Indexed keywords

ACETYLCHOLINE; BRADYKININ; CALCIMYCIN; ENDOTHELIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) NITROARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROSTACYCLIN; VASOACTIVE AGENT;

ADAPTATION; BLOOD VESSEL; BLOOD VESSEL REMODELING; CHILD; CHILDHOOD; CONFERENCE PAPER; DEVELOPMENT; FAMILIAL DISEASE; GENETIC ANALYSIS; HEMODYNAMICS; HUMAN; HYPOXIA; IMMUNE SYSTEM; INFANT; NEWBORN; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

EID: 0035004411     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(01)00077-7     Document Type: Conference Paper

References (152)

1. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32
2. Primary pulmonary hypertension: a national prospective study
3. Familial primary pulmonary hypertension
4. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension
5. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors
6. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
7. Controlling TGF-β signalling
8. Transforming growth factor-beta in disease: the dark side of tissue repair
9. 2+ channel that is regulated by TGF-β
10. Pulmonary hypertension 'plexogenic pulmonary arteriopathy' and the appetite depressant drug aminorex: post or propter?
11. The acute administration of vasodilators in primary pulmonary hypertension
12. Enhanced ET(A) receptor-mediated inhibition of K(v) channels in hypoxic hypertensive rat pulmonary artery myocytes
13. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction
14. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension
15. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?
16. Nitric Oxide and endothelin-1 in pulmonary hypertension
17. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
18. Lipid mediator disregulation in primary pulmonary hypertension
19. Significance of high plasma serotonin in primary pulmonary hypertension
20. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin
21. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat
22. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
23. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis
24. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension
25. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
26. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension
27. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension
28. Plasma coagulation profiles in patients with severe primary pulmonary hypertension
29. Continuous infusion of prostacyclin normalises plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension
30. Primary pulmonary hypertension in children
31. Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex
32. Autoimmune protein S deficiency in a boy with severe thromboembolic disease
33. Primary pulmonary hypertension associated with human immunodeficiency virus infection
34. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection
35. Role of human immunodeficiency virus in primary pulmonary hypertension case reports
36. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
37. Onset and evolution of pulmonary vascular disease in young children: abnormal postnatal remodelling studied in lung biopsies
38. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics
39. Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations
40. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease
41. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease
42. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man
43. Effect of intracardiac repair on thromboxane A2 and prostacyclin biosynthesis in children with a left to right shunt
44. Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects
45. Effects of cardiopulmonary bypass and circulatory arrest on endothelium-dependent vasodilatation in the lung
46. Elastase activity and the pathophysiology of pulmonary hypertension
47. Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood
48. Lung biopsy findings in transposition of the great arteries with ventricular septal defect: potentially reversible pulmonary vascular disease is not always synonymous with operability
49. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease
50. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
51. Vascular endothelial growth factor stimulates collateral formation by inducing arterial cell proliferation in a rabbit ischemic hindlimb
52. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intra-cardiac repair
53. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease
54. Spatial relationships in early signalling events of flow-mediated endothelial mechanotransduction
55. Mechanotransduction in endothelial cells: temporal signalling events in response to shear stress
56. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress
57. Fluid shear stress stimulates mitogen-activated protein kinase in endothelial cells
58. MAP kinase activation by flow in endothelial cells: role of β1 integrins and tyrosine kinases
59. Stimulation of transcription factors NF kappa B and AP1 in endothelial cells subjected to shear stress
60. Nuclear factor-kappa B interacts functionally within the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress
61. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element
62. Hemodynamic forces are complex regulators of endothelial gene expression
63. Subcellular distribution of shear stress at the surface of flow aligned and non-aligned endothelial monolayers
64. Quantitative studies of endothelial cell adhesion: directional remodelling of focal adhesion sites in response to flow forces
65. Integrin signalling transduces shear stress-dependent vasodilation of coronary arterioles
66. Overview: temporal and spatial relationships in shear stress-mediated endothelial signalling
67. + current in vascular endothelial cells
68. Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat myocytes - possible role of protein kinase C activation
69. Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF
70. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress
71. Impairment of pulmonary artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to dysfunction of endothelial cell membrane receptors nor to L-arginine deficiency
72. 3H]-thymidine by cells of the rat pulmonary arteries and alveolar wall
73. Protein kinase C activation allows pulmonary artery smooth muscle cells to proliferate to hypoxia
74. Unique growth properties of neonatal pulmonary vascular cells: importance of time and site-specific responses, cell-cell interation, and synergy
75. Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities
76. Hypoxia inhibits l-arginine uptake by pulmonary artery endothelial cells
77. Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation
78. Nitric oxide and nitric oxide-generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding
79. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells
80. Endothelial heparan sulfate proteoglycan I. Inhibitory effects on smooth muscle cell proliferation
81. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide
82. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase
83. Influence of hypoxia on endothelin-1 binding sites in neonatal porcine pulmonary vasculature
84. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia
85. Increased endothelin receptor gene expression in hypoxic rat lung
86. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension
87. Introduction of serotonin transporter of hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin
88. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor
89. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells
90. Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension
91. Hypoxic induction of interleukin-8 gene expression in human endothelial cells
92. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia
93. Purification and characterization of hypoxia-inducible factor 1
94. Activation of hypoxia-inducible factor 1? Post-transcriptional regulation and conformational change by recruitment of the Arnt transcription factor
95. Gene regulation during hypoxia
96. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kB and AP-1
97. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein
98. Oxygen regulated transcription of cytochrome c and cytochrome c oxidase genes in yeast
99. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans
100. A study of nerves containing peptides in the pulmonary vasculature of healthy infants and children and of those with pulmonary hypertension
101. Persistent fetal circulation: newly recognised structural features
102. Normal adaptation of pulmonary arterial intima to extrauterine life in the pig: ultrastructural studies
103. Thinning of fetal pulmonary arterial wall and postnatal remodelling: ultrastructural studies on the respiratory unit arteries of the pig
104. Neonatal pulmonary hypertension prevents reorganisation of the pulmonary arterial smooth muscle cytoskeleton after birth
105. Bromodeoxyuridine labelling and DNA content of pulmonary arterial medial cells from normal and hypoxia exposed calves
106. Role of the vascular smooth muscle in connective tissue production during development and disease
107. Smooth muscle mediated connective tissue remodelling in pulmonary hypertension
108. Regulation of collagen production by medial smooth muscle cells in hypoxic pulmonary hypertension
109. 3H]thymidine pulse-labelling of intimal, medial, and adventitial cells in microvessels and at the hilum
110. Proliferative changes in the pulmonary arterial wall during short-term hyperoxic injury to the lung
111. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin
112. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with non- progressive disease
113. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity
114. SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats
115. Role of prostaglandins, thromboxanes and leukotrienes in the control of the pulmonary circulation in the fetus and newborn
116. Pulmonary haemodynamics after synthetic surfactant replacement in neonatal RDS
117. Leukotriene end organ antagonists increase pulmonary blood flow in fetal lambs
118. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth
119. Nw-nitro-l-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs
120. Maturational changes in endothelium-derived relaxing factor activity of ovine pulmonary arteries in vitro
121. Developmental changes in endothelium-dependent pulmonary vasodilatation in pigs
122. Chronic hypoxia inhibits postnatal maturation of porcine intrapulmonary artery relaxation
123. Maturation of the response to bradykinin in resistance and conduit pulmonary arteries
124. Newborn intrapulmonary veins are more reactive than intrapulmonary arteries in normal and hypertensive piglets
125. Endothelium-derived nitric oxide plays a larger role in pulmonary veins than in arteries of newborn lambs
126. Muscarinic receptor subtypes in the porcine lung during postnatal development
127. Abundance of endothelial nitric oxide synthase in newborn intrapulmonary arteries
128. Constitutive endothelial nitric oxide synthase gene expression is regulated during lung development
129. Changes in nitric oxide synthase activity in the porcine lung
130. Asymmetric dimethyl arginine in infants with persistent pulmonary hypertension of the newborn
131. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase
132. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development
133. Resting potentials and potassium currents during the development of pulmonary artery smooth muscle cells
134. Endothelial nitric oxide synthase in hypoxic newborn porcine pulmonary vessels
135. Co-ordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs
136. Altered endothelium-dependent vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow
137. EDRF inhibition augments pulmonary hypertension in intact newborn lambs
138. L-arginine restores endothelium-dependent relaxation in pulmonary circulation of chronically hypoxic rats
139. +-pump inhibitors and membrane depolarizing agents on acetylcholine-induced endothelium-dependant relaxation and cyclic GMP accumulation in rat aorta
140. +(ATP)-channel activation in isolated normal and hypertensive newborn and adult porcine pulmonary vessels
141. Diversity of response in vascular smooth muscle cells to changes in oxygen tension
142. Developmental changes in prostacyclin synthesis are conserved in cultured pulmonary endothelium and vascular smooth muscle
143. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction
144. Postnatal changes in endothelin-1 binding in porcine pulmonary vessels and airways
145. Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist, BQ-153
146. Effects of age and hypoxia on bradykinin-induced bronchial responses
147. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat
148. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation
149. The role of NO in recovery from neonatal hypoxic pulmonary hypertension